Successful testing protocols in virology

Clinical Chemistry

Volumn 47, Issue 8, 2001, Pages 1559-1562

  Kelley, V A ^a   Caliendo, A M ^a  

^a EMORY UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONFERENCE PAPER; CYTOMEGALOVIRUS; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; GENOTYPE; HEPATITIS C VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1; MOLECULAR BIOLOGY; SENSITIVITY AND SPECIFICITY; VIRUS DETECTION; VIRUS INFECTION;

EID: 0034912151     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1093/clinchem/47.8.1559     Document Type: Conference Paper

References (20)

1. Clinical utility of quantitative cytomegalovirus viral load determination for predicting cytomegalovirus disease in liver transplant recipients
2. Use of molecular assays in diagnosis and monitoring of cytomegalovirus disease following renal transplantation
3. Cytomegalovirus (CMV) DNA load predicts relapsing CMV infection after solid organ transplantation
4. Comparison of quantitative cytomegalovirus (CMV) PCR in plasma and CMV antigenemia assay: Clinical utility of the prototype AMPLICOR CMV MONITOR test in transplant recipients
5. Antiretroviral therapy in adults: Updated recommendations of the International AIDS Society-USA Panel
6. Antiretroviral drug resistance testing in adults with HIV infection: Implications for clinical management. International AIDS Society-USA Panel
7. Drug-resistance genotypying in HIV-1 therapy: The VARADAPT randomised controlled trial
8. A randomized study of antiretroviral management based on plasma genotypic antiretroviral resistance testing in patients failing therapy
9. Persisting long-term benefit of genotype-guided treatment for HIV-infected patients failing HAART. The Viradapt Study: Week 48 follow-up
10. Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an International AIDS Society-USA panel
11. National Institutes of Health Consensus Development Conference Panel Statement: Management of hepatitis C
12. Epidemiology of hepatitis C
13. Long-term mortality after transfusion-associated non-A, non-B hepatitis
14. Clinical outcomes after transfusion-associated hepatitis C
15. Liver transplantation for chronic viral hepatitis
16. Application of six hepatitis C virus genotyping systems to sera from chronic hepatitis C patients in the United States
17. Group ftHIT interferon α-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C
18. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus